Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
NCT ID: NCT05539677
Last Updated: 2024-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
1998-09-30
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401
Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.
NCT00974610
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
NCT02105168
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
NCT05530759
Biomarker Research for Personalized Medicine
NCT01488591
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Melanoma
No interventions assigned to this group
Soft tissue sarcoma
No interventions assigned to this group
Kidney cancer
No interventions assigned to this group
Primary brain tumors
No interventions assigned to this group
Malignant neoplasms
No interventions assigned to this group
Prostate cancer
No interventions assigned to this group
Colorectal cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histolgically verified solid tumour
* Receiving systemic therapy for neoplasm
* Has archival tumour tissue
* Provide biosamples with living tumour tissue or blood samples for immunologic assessment
Exclusion Criteria
* Patients after stem cell or bone marrow thansplantation
* Incomplete informaton on previous cancer history or medical history
* Patients with known primary immunodeficiency
* Patients receiving immunosupressive therapy for concurrent illness
* Pregnant patients
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
N.N. Petrov National Medical Research Center of Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Irina Baldueva, MD, PhD, DSc
Role: STUDY_DIRECTOR
N.N. Petrov NMRC of Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
N.N. Petrov NMRC of Oncology, Oncoimmunology dep.
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Shendaleva N, Novik AV, Zozulya A, Nekhaeva TL, Semenova A, Teletaeva GM, et al. Impact of the azoximer bromide concomitant therapy on patient outcomes in patients with melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(15_suppl):e21574-e.
Novik AV, Shendaleva N, Zozulya A, Nekhaeva TL, Semenova A, Teletaeva GM, et al. Impact of the azoximer bromide concomitant therapy on outcomes in patients with soft tissue sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(15_suppl):e23534-e.
Novik AV, Girdyuk DV, Nekhaeva TL, Emelyanova NV, Semenova A, Teletaeva GM, et al. Progression prediction model for solid tumors with clinical and immunological parameters. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(15_suppl):2539.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAA-A18-118032890188-9
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.